Barclays analyst Glen Santangelo lowered the firm’s price target on Bausch Health (BHC) to $7 from $8 and keeps an Equal Weight rating on the shares post the Q4 report. The firm continues to see loss of exclusivities weighing on the company in 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC: